Trademark: 88443079
Word
THERADIGM
Status
Dead
Status Code
606
Status Date
Monday, January 2, 2023
Serial Number
88443079
Mark Type
4000
Filing Date
Thursday, May 23, 2019
Published for Opposition
Tuesday, October 1, 2019
Abandoned Date
Monday, January 2, 2023

Trademark Owner History
Vesta Therapeutics, Inc. - Owner At Publication

Classifications
40 Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process
5 Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
1 Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
44 Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
42 Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells

Trademark Events
Jan 3, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Jan 2, 2023
Abandonment - No Use Statement Filed
May 24, 2022
Notice Of Approval Of Extension Request E-Mailed
May 23, 2022
Sou Extension 5 Granted
May 18, 2022
Sou Extension 5 Filed
May 23, 2022
Case Assigned To Intent To Use Paralegal
May 18, 2022
Sou Teas Extension Received
Jan 28, 2022
Assigned To Examiner
Oct 28, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 26, 2021
Sou Extension 4 Granted
Oct 26, 2021
Sou Extension 4 Filed
Oct 26, 2021
Sou Teas Extension Received
Apr 29, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 27, 2021
Sou Extension 3 Granted
Apr 27, 2021
Sou Extension 3 Filed
Apr 27, 2021
Sou Teas Extension Received
Nov 18, 2020
Notice Of Approval Of Extension Request E-Mailed
Nov 16, 2020
Sou Extension 2 Granted
Nov 16, 2020
Sou Extension 2 Filed
Nov 16, 2020
Sou Teas Extension Received
May 9, 2020
Notice Of Approval Of Extension Request E-Mailed
May 7, 2020
Sou Extension 1 Granted
May 7, 2020
Sou Extension 1 Filed
May 7, 2020
Sou Teas Extension Received
Nov 26, 2019
Noa E-Mailed - Sou Required From Applicant
Oct 1, 2019
Official Gazette Publication Confirmation E-Mailed
Oct 1, 2019
Published For Opposition
Sep 11, 2019
Notification Of Notice Of Publication E-Mailed
Aug 29, 2019
Assigned To Lie
Aug 21, 2019
Approved For Pub - Principal Register
Aug 19, 2019
Examiner's Amendment Entered
Aug 19, 2019
Notification Of Examiners Amendment E-Mailed
Aug 19, 2019
Examiners Amendment E-Mailed
Aug 19, 2019
Examiners Amendment -Written
Aug 13, 2019
Assigned To Examiner
Jun 7, 2019
New Application Office Supplied Data Entered
May 27, 2019
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24